Skip to content

Cancer Health Center

Font Size

Laboratory / Animal / Preclinical Studies

    In 1978 and 1980, the National Cancer Institute (NCI) tested Cancell/Cantron/Protocel in animal studies and determined that the mixture lacked substantial antitumor activity. Reviewed in [1]

    In 1990 and 1991, samples of Cancell/Cantron/Protocel were evaluated in NCI's in vitro NCI-60 DTP Human Tumor Cell Line Screen. In the screen, the cell lines are grown in artificial media under conditions that do not truly mimic the in vivo situation in animals or humans. The important information used in assessing a drug's effectiveness in the NCI in vitro screen includes drug concentrations necessary to achieve the following:

    1. 50% inhibition of cell growth (GI50; the concentration needed to reduce the growth of treated cells to half that of untreated [i.e., control] cells).
    2. 100% (total) growth inhibition (TGI; the concentration required to completely halt the growth of treated cells).
    3. 50% cell kill or lethal concentration (LC50; the concentration that kills 50% of treated cells).

    The log10 values for GI50, TGI, and LC50 for the 60 cell lines are available online.

    The variations in log10 values for GI50 are 0.4 to 1.8 (mean = 1.15), equivalent to concentrations of 2.5 to 63 μg /mL (mean = 14); the variations in log10 values for TGI are 1.0 to 2.5 (mean = 1.62), equivalent to 10 to 320 μg/mL (mean = 41); and the variations in log10 values for LC50 are 1.6 to 3.9 (mean = 3.17), equivalent to 39 to 7,943 μg/mL (mean = 1,479).

    Cancell/Cantron/Protocel Tumor Cell Line Screen Results

    Parameter Measured60 Cell-line Range (μg/mL)Mean (μg/mL)
    50% growth inhibition (GI50)2.5–6314
    Total growth inhibition (TGI)10–32041
    Concentration for 50% lethality (LC50)39–7,9431,479
    Maximum theoretical humanplasmaconcentration (for comparison)29 (calculated)

    Based on the manufacturer's recommended doses of a marketed brand of Cancell/Cantron/Protocel it has been calculated that under idealized conditions of absolutely no loss of the constituents after administration to a patient (i.e., 100% bioavailability, meaning no loss due to degradation, absorption in the body, or rapid excretion—an unlikely situation), the maximum concentration that could be achieved in the plasma of an average 154-lb male is 29 μg/mL (antilog of 1.46). Thus, under these highly idealized conditions Cancell/Cantron/Protocel may exhibit some mild inhibitory effect on the growth of some cancer cells, but it would not be expected to inhibit their growth completely or to kill them. There is little evidence that any of the constituents of Cancell/Cantron/Protocel would be available in the bloodstream of a patient.


      Today on WebMD

      Colorectal cancer cells
      A common one in both men and women.
      Lung cancer xray
      See it in pictures, plus read the facts.
      sauteed cherry tomatoes
      Fight cancer one plate at a time.
      Ovarian cancer illustration
      Do you know the symptoms?
      Jennifer Goodman Linn self-portrait
      what is your cancer risk
      colorectal cancer treatment advances
      breast cancer overview slideshow
      prostate cancer overview
      lung cancer overview slideshow
      ovarian cancer overview slideshow
      Actor Michael Douglas